Kidney Week

Abstract: SA-PO1135

Retrospective Audit on the Efficacy and Safety of Methenamine Hippurate in Preventing Recurrent Urinary Tract Infection Among Kidney Transplant Recipients

Session Information

• Transplantation: Clinical - Infectious Diseases
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2002 Transplantation: Clinical

Authors

• Jahmeerbaccus, Nabeelah B., Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom

Nabeelah B. Jahmeerbaccus, MBChB, MSc

• Sinha, Tanvi, Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom

Tanvi Sinha, MBChB

• Ramakrishnan Chandrababu, Varshika, Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom

Varshika Ramakrishnan Chandrababu, MBBS

• Korim, Mohammad Noorani Rahim, Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom

Mohammad Noorani Rahim Korim

• Farrugia, Daniela, Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom

Daniela Farrugia, MD

Background

Renal transplant recipients are at high risk of urinary tract infections (UTI) due to immunosuppression, comorbidities and urological abnormalities. While Methenamine Hippurate is an established non-antibiotic antiseptic, data on its safety and efficacy in the transplant population are limited

Methods

We conducted an audit of patients on Methenamine Hippurate known to our renal department. Data were retrieved from electronic health records that included clinic and discharge letters as well as laboratory values.

All patients above 18 years old with a documented UTI and on Methenamine Hippurate were included. The primary outcome was the difference in number of UTI at 12 months post Methenamine Hippurate use. The secondary outcome measure was the proportion of patients who had to stop the medication due to adverse events.

Results

31 renal transplant recipients were found to be on Methenamine Hippurate and therefore included in this audit.

All of them were on immunosuppression and were taking Methenamine Hippurate at the standard dose of 1g twice daily.

The number of UTI episodes pre and post Methenamine Hippurate was investigated including the number of admissions. The change in eGFR and any adverse event were recorded.

Conclusion

Methenamine Hippurate was a safe and effective non-antibiotic strategy in reducing UTI in renal transplant recipients, causing minimal adverse events and no significant impact on graft function.

Efficay of Methenamine Hippurate in reducing UTI episodes and hospitalisations